SCHEMBL578916

SCHEMBL578916

CCOC(=O)C(CC)(CC)P(=O)(O)OF

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
MMP8 P22894 2/20 0.34
PKM P14618 3/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
THRB P10828 1/20 0.33
LMNA P02545 2/20 0.32
HSD17B10 Q99714 1/20 0.32
HTT P42858 1/20 0.32
ALOX15 P16050 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10930331 0.83 CYP4F2 (0.37) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL5451691 0.83 MAPT (0.37) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL3133963 0.81 CYP4F2 (0.36) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL1072447 0.81 CYP4F2 (0.36) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL16048 0.80 CYP4F2 (0.40) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL18759662 0.80 CYP4F2 (0.40) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL543816 0.80 CYP4F2 (0.35) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL413276 0.79 CYP4F2 (0.39) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL19278938 0.79 CYP4F2 (0.39) CYP4F2CYP4A11MMP8PKMALDH1A1
SCHEMBL8045727 0.77 MMP8 (0.35) CYP4F2CYP4A11MMP8PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed
US-9861652-B2 2′ Fluoronucleosides EMORY UNIVERSITY (US) 2018-01-09 US disclosed
US-20160158266-A1 2' FLUORONUCLEOSIDES EMORY UNIVERSITY 2016-06-09 US disclosed
EP-1861401-B1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2015-11-18 EP disclosed
US-9180138-B2 2′-fluoronucleosides UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2015-11-10 US disclosed
EP-2417141-B1 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY ACTELION PHARMACEUTICALS LTD (CH) 2013-10-16 EP disclosed
US-20130157971-A1 2'-FLUORONUCLEOSIDES SCHINAZI RAYMOND F (US) 2013-06-20 US disclosed
US-8415375-B2 2-hydroxyethyl-1H-quinolin-2-one derivatives and their azaisosteric analogues with antibacterial activity ACTELION PHARMACEUTICALS LTD. (CH) 2013-04-09 US disclosed
EP-0449884-A4 DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS 1991-10-30 EP disclosed
EP-0449884-A1 DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS ABBOTT LABORATORIES (US) 1991-10-09 EP disclosed
WO-1990006937-A1 DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS ABBOTT LABORATORIES (US) 1990-06-28 WO disclosed
US-4375563-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1983-03-01 US disclosed
US-4338253-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1982-07-06 US disclosed
US-4321209-A Fluorinated aromatic polyenes HOFFMANN-LA ROCHE INC. (US) 1982-03-23 US disclosed
US-4266073-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1981-05-05 US disclosed
US-4201727-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1980-05-06 US disclosed
US-4169100-A FLUORO AND TRIFLUOROMETHYL SUBSTITUTED 9-(4-ALKOXY-2,3,6-TRIALKYLPHENYL)-2,4,6,8-NONATETRAENOIC ACIDS, ESTERS AND AMIDES, ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1979-09-25 US disclosed
US-4137246-A ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 CYP4F2 444/4885CYP4A11 329/4885MMP8 301/4885
US-20160158266-A1 2' FLUORONUCLEOSIDES PNP, BCL3, NPC1 CYP4F2 758/4885CYP4A11 750/4885MMP8 3390/4885
US-20130157971-A1 2'-FLUORONUCLEOSIDES PNP, BCL3, FUBP3 CYP4F2 760/4885CYP4A11 707/4885MMP8 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.